Valence Labs
The AI engine Fit Assessment
BetaValence Labs effectively leverages machine learning to discover patterns and expand therapeutics, while optimizing the drug discovery process.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Drug Discovery Optimization
Developer of artificial intelligence-based drug discovery platform designed to unlock small and noisy datasets. The company's platform uses bioinformatics and artificial intelligence to optimize the development of drugs through predictive analytics and work with the small and noisy datasets characteristic of low-throughput compound screens and late-stage lead optimization, enabling pharmaceutical companies to reduce the time, design, and optimize novel ligands against a broad range of precision medicine targets.